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treatment was based on stage and prognostic score. Other model inputs were 
literature-derived or assumption-based. Costs and QALYs were discounted at a 
3% annual rate. One-way and probabilistic sensitivity analyses examined the rela-
tive impact of model inputs. Results: In the base case scenario 44% of patients 
received ACT using the prognostic test vs. 38% based on SoC. Total costs were 
$131,287 and $125,594 and total QALYs gained were 5.33 and 5.16 for the prognos-
tic test and SoC, respectively. The incremental cost-effectiveness ratio (ICER) for 
the prognostic test was $34,055/QALY gained. One-way sensitivity analyses indi-
cated the probability of receiving ACT for high-risk, stage Ib patients and the ACT 
treatment benefit were the largest drivers of cost-effectiveness. The probabilistic 
sensitivity analysis ICER was $44,196/QALY gained. The prognostic test was cost-
effective in 51.1% of the simulations at a willingness-to-pay threshold of $50,000/
QALY gained. ConClusions: The results of this study suggest that using myPlan 
Lung Cancer to guide ACT decisions is cost-effective compared to a SoC approach 
according to globally accepted thresholds.
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objeCtives: The Breast Cancer Trials of Oral Everolimus-2 (BOLERO-2) is a double-
blind, phase 3 trial that compared Everolimus plus Exemestane (n = 485) versus 
placebo plus Exemestane (n= 239). Postmenauposal women with advanced hormone 
receptor positive breast cancer (ABC) were included in the study. The trial demon-
strated that Everolimus plus Exemestane significantly prolonged progression-free 
survival (PFS). PFS as an outcome measure to compare treatment strategies for ABC 
is incomplete as it fails to account for the quality of life of patients living in that dis-
ease state. To address this issue, researchers can estimate the quality adjusted pro-
gression free survival (QAPFS) of treatments as an effectiveness measure. This study 
aims to estimate the QAPFS of the treatment arms of the BOLERO-2 trial. Methods: 
For each treatment arm of the trial, QAPFS was estimated by multiplying the overall 
health utility weights associated with PFS (taking into consideration disutlities asso-
ciated with the adverse events of treatments) by the corresponding mean PFS time. 
Health utility data were obtained from the literature, while mean PFS times were 
estimated through the survival analysis of the reconstructed individual patient data 
of the BOLERO-2 trial. Results: Progression free survival (robust mean; (95% robust 
confidence interval) was 44.73 weeks (41.03; 48.43) for Evrolimus + Exemestane 
and 22.98 weeks (19.88; 26.08) for Placebo + Exemestane. The QAPFS (robust mean, 
(95% robust confidence interval) for the treatment arms of the trial were respec-
tively 1.67 (1.53; 1.81) for Evrolimus + Exemestane and (0.78; 1.02) for Placebo + 
Exemestane. ConClusions: Using QAPFS as the outcome measure provides a 
better assessment of the benefit induced by the treatment arms of the BOLERO-2 
trial. The benefit of Everolimus + Exemestane over Placebo + Exemestane observed 
in the trial was maintained in this analysis. The estimates obtained as part of our 
analysis can be used in future cost effectiveness studies.
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mortality rate at 5 years following treatment as well as recurrence rates following 
chemo-radiation. ConClusions: Cost-utility analysis comparing chemo-radiation 
to cystectomy as primary treatment for MIBC reveals that chemo-radiation is not 
cost-effective when compared to cystectomy.
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objeCtives: To determine the value of different mammography screening modali-
ties from the societal context. Methods: The Wisconsin CISNET breast cancer 
model was adapted to reflect the Canadian context (incidence, resource utilization 
and unit costs (2012 CAN$)). Predictions were made of age-specific breast cancer 
incidence for a 1960 birth cohort of 2,000,000 women for a number of screening sce-
narios varied by age bands (start at 40 or 50 years, end at 69 or 74 years), frequency 
(annual, biennial, triennial) from a societal perspective. Incremental cost-effec-
tiveness and cost-utility analyses were examined for different screening scenarios 
compared to the basecase (biennial 50 to 74 years). A 5% discount rate was used. 
Sensitivity analyses considered screening tool performance, compliance, costs and 
treatments. Results were expressed for 1,000 women alive at age 40 years. Results: 
Our model showed that all annual screening strategies were found to be more 
effective than the basecase. The most aggressive annual screening scenario (40 
to 74 years) saved the lives of 21 more women per 1,000 than the basecase at an 
additional $3,800 per woman. Our model predicted that annual screening from age 
40 to 74 years had a slightly lower incremental ratio compared to annual 40 to 49, 
biennial 50 to 74 years when compared to the basecase. Cost drivers were discount 
rate, screening frequency, utility values, treatment and sensitivity of mammogra-
phy. ConClusions: The greatest single cost contributor in a screening program 
is the mammography itself. The more screens that a women receives in her life, 
the greater the financial cost to society. Because both the life savings and costs rise 
together almost linearly with the number of lifetime screens per women, the deci-
sion on how to screen is mainly related to willingness to pay and avoiding recalling 
too many women for further examinations after positive screens.
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objeCtives: Analyzing the cost-effectiveness of blood cancer-related therapies 
has become more important as expensive drugs have been introduced. This study 
reviewed cost-utility analyses (CUAs) of innovative blood cancer-related interven-
tions and examined the number and methodology of studies and the cost-utility 
ratios. Methods: We analyzed studies related to blood cancers from the Tufts 
Cost-Effectiveness Analysis Registry (www.cearegistry.org), a database including 
over 9,800 CEAs published through 2012. We focused on innovative agents and 
excluded hematopoietic stem cell transplant, symptom management, and sup-
portive care. Studies that met the inclusion criteria were categorized by four cancer 
types (chronic myeloid leukemia (CML), chronic lymphocytic leukemia (CLL), non-
Hodgkin’s lymphoma (NHL), and multiple myeloma (MM)) and nine treatment types 
(α interferon, alemtuzumab, bendamustine, bortezomib, dasatinib, imatinib, leno-
lidomide, rituximab alone or in combination, and thalidomide). Cost-effectiveness 
ratios were stratified by funder and cancer type. Results: Twenty-nine studies 
published from 1996-2012 (including 44 cost-effectiveness ratios) met the inclusion 
criteria. Thirty-one percent were conducted in the US. The majority (62%) used the 
health care payer perspective; 24% used the recommended societal perspective. 
Seventy-six percent were industry-funded. In 21%, economic data were collected 
alongside a clinical trial. Most ratios pertained to NHL (41%) or CML (30%) and to 
treatment with rituximab (43%), α interferon (18%), or imatinib (16%). Across cancers, 
the median ratio was highest for CML ($55,000/QALY) and lowest for NHL ($21,500/
QALY). Median ratios over time were $35,000/QALY (1996-2002), $52,000/QALY (2003-
2006), and $22,000/QALY (2007-2012). A majority of ratios (73%) fell below $50,000/
QALY, and most (86%) fell below $100,000/QALY. The median was lower for indus-
try-funded studies ($26,000/QALY) than others ($33,000/QALY). ConClusions: 
Published CUAs of these blood cancer treatments demonstrate relatively good 
value. While the treatments may have high unit prices, many also seem to confer 
considerable health benefits at reasonable overall costs.
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objeCtives: Limited guidance exists for health care providers deciding when to 
treat patients with adjuvant chemotherapy (ACT) in early NSCLC. This leads to 
high-risk untreated patients that could benefit, and low-risk patients who could 
avoid the toxicity and cost, from ACT. This study examined the cost-effectiveness 
of the prognostic test myPlan Lung Cancer vs. current standard of care (SoC) in 
directing ACT treatment decisions in stage I/II NSCLC. Methods: A Markov model 
was created to examine costs (2011 US$) and effectiveness (quality-adjusted life-
years [QALYs]), from a US third-party payer perspective over a lifetime horizon. 
Patients were classified as high or low risk based on a prognostic score derived 
from stage and an expression signature based on cell cycle progression. The prob-
ability of receiving ACT was estimated from a physician survey. Benefit of ACT 
